Search This Blog

Tuesday, March 3, 2026

Esperion Therapeutics to acquire Corstasis Therapeutics

 

 for $75M cash plus up to $180M in milestones and royalties, adding FDA-approved Enbumyst to cardiovascular franchise

  • Closing of the Corstasis Therapeutics acquisition is expected in Q2 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)